{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:42:22Z","timestamp":1790660542089,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C\u2010C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T\u2010cell lymphoma (CTCL): S\u00e9zary syndrome (SS) or Mycosis Fungoides (MF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The real\u2010world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 122 analysed patients (69 SS, 53 MF) were aged 66.6\u2009\u00b1\u200912.1\u2009years at mogamulizumab initiation, and their median disease duration was 2.5\u2009years (IQR: 1.3\u20135.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2\u20135). Overall, 77.8% of patients suffered from advanced disease (Stage IIB\u2013IVB), with frequent blood (B1\/B2) involvement (67.5%). Over the treatment period (median: 4.6\u2009months, 2.1\u20137.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9\u201368.1]) overall, 69.5% [56.1\u201380.8] in SS and 46.0% [31.8\u201360.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1\u201390.9] of SS patients. Skin responses were observed in 57.0% [47.0\u201366.5] of patients overall, 66.7% [52.9\u201378.6] in SS and 46.0% [31.8\u201360.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion\u2010related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab\u2010related tumour lysis syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19134","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T01:19:44Z","timestamp":1682644784000},"page":"1777-1784","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: A multicentre, retrospective, real\u2010world French study"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"M.","family":"Beylot\u2010Barry","sequence":"first","affiliation":[{"name":"BoRdeaux Institute of Oncology, INSERM U1312, Team 5 Bordeaux University  Bordeaux France"},{"name":"Dermatology Department CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Quereux","sequence":"additional","affiliation":[{"name":"Dermatology Department, Nantes University Hospital University of Nantes, CIC 1413, INSERM UMR 1302\/EMR6001 INCIT  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nardin","sequence":"additional","affiliation":[{"name":"Dermatology Department, Minjoz Hospital CHU Besancon  Besancon France"},{"name":"INSERM U1098 University of Franche Comt\u00e9, EFS Bourgogne Franche\u2010Comt\u00e9 and Franche\u2010Comt\u00e9 University  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.\u2010B.","family":"Duval\u2010Modeste","sequence":"additional","affiliation":[{"name":"Department of Dermatology, INSERM U519 Rouen University Hospital  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-1922","authenticated-orcid":false,"given":"O.","family":"Dereure","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalac\u2010Rat","sequence":"additional","affiliation":[{"name":"Dermatology Department Dijon Bourgogne University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dobos","sequence":"additional","affiliation":[{"name":"Dermatology Department Saint\u2010Louis Hospital, AP\u2010HP  Paris France"},{"name":"INSERM U976 Human Immunology Pathophysiology and Immune Therapies  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Department of Dermatology, HTCC Charit\u00e9\u2010Universitaetsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-6084","authenticated-orcid":false,"given":"A.","family":"Pham\u2010Ledard","sequence":"additional","affiliation":[{"name":"BoRdeaux Institute of Oncology, INSERM U1312, Team 5 Bordeaux University  Bordeaux France"},{"name":"Dermatology Department CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ram\u2010Wolff","sequence":"additional","affiliation":[{"name":"Dermatology Department Saint\u2010Louis Hospital, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D'Incan","sequence":"additional","affiliation":[{"name":"Dermatology and Cutaneous Oncology, Estaing University Hospital University of Clermont\u2010Ferrand  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grange","sequence":"additional","affiliation":[{"name":"Department of Dermatology Valence Hospital  Valence France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-3609","authenticated-orcid":false,"given":"V.","family":"Braniste","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Pharma, Medical Affairs  Neuilly\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-5192","authenticated-orcid":false,"given":"M.","family":"Bagot","sequence":"additional","affiliation":[{"name":"Dermatology Department Saint\u2010Louis Hospital, AP\u2010HP  Paris France"},{"name":"INSERM U976 Human Immunology Pathophysiology and Immune Therapies  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19644"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2010.06.021"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19669"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2191"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency.Poteligeo. Summary of product characteristics. [last accessed 2022 Nov 08]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/poteligeo\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071659"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08363-w"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17523"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(21)00714-0"},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency.Committee for medicinal products for human use. Assessment report. POTELIGEO. 2018 Sep 20 [last accessed 2022 Nov 08]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/poteligeo\u2010epar\u2010public\u2010assessment\u2010report_en.pdf"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21030"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0369"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18284"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013341"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(21)00712-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0877"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00624-7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2003.008466"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:04:05Z","timestamp":1692936245000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/jdv.19134"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19134","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"2022-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}